| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-06-12 | Janssen R&D Ireland, a J&J company (Ireland - USA) - ViiV Healthcare (USA - UK) | single tablet regimen containing Janssen\'s rilpivirine (Edurant®) and ViiV\'s dolutegravir (Tivicay®) | maintenance treatment of people living with Human Immunodeficiency Virus (HIV) | development commercialisation |
Infectious diseases | Development agreement |
| 2014-06-12 | AstraZeneca (UK) Synairgen (UK) | SNG001 | respiratory tract viral infections in patients with severe asthma | licensing |
Infectious diseases - Respiratory diseases - Allergic diseases | Licensing agreement |
| 2014-06-10 | Argen-X (The Netherlands-Belgium) The Leukemia & Lymphoma Society | ARGX-110 | refractory Waldenström’s macroglobulinemia | clinical research |
Rare diseases - Cancer - Oncology | Clinical research agreement |
| 2014-06-10 | Beactica (Sweden) Medivir (Sweden) | novel hits against a disease-relevant protease | undisclosed | R&D |
undisclosed | R&D agreement |
| 2014-06-10 | Synthetic Biologics (USA - MD) Enterome Bioscience (France) | SYN-004, beta-lactam antibiotics | C. difficile infections | R&D |
Infectious diseases | R&D agreement |
| 2014-06-09 | Cellectis (France) CELLforCure (France) | allogeneic CART cells | manufacturing production |
Cancer - Oncology | Production agreement | |
| 2014-06-09 | ImaginAb (USA - CA) IBA Molecular (Belgium) | 89Zr-Df-IAB2M | prostate cancer | manufacturing production |
Cancer - Oncology - Technology - Services | Production agreement |
| 2014-06-06 | Antitope, an Abzena company (UK) Baylor Institute for Immunology Research (USA) | manufacturing cell line for the production of al dendritic-cell-targeting vaccine | head and neck cancer - cervical cancer | development |
Technology - Services - Cancer - Oncology | Development agreement |
| 2014-06-04 | Genmab (Denmark) - undisclosed large Biotechnology company | DuoBody® and HexaBody™ technology platforms | undisclosed | R&D |
undisclosed | R&D agreement |
| 2014-06-04 | Medimmune (USA - global biologics arm of AstraZeneca (UK) - Ventana Medical Systems,(USA), a member of the Roche Group (Switzerland) | PD-L1 (SP263) immunohistochemistry assay for MEDI4736 anti-PD-L1 immunotherapy's clinical trials | non-small cell lung carcinoma | development |
Cancer - Oncology | Development agreement |
| 2014-06-04 | NeuroVive Pharmaceutical (Sweden) Hospices Civils de Lyon (France) | CicloMulsion® cremophor-free IV cyclosporine formulation | development |
Cardiovascular diseases | Development agreement | |
| 2014-06-03 | ImaginAb (USA - CA) University of California, Los Angeles (UCLA) (USA - CA) | immune cell-targeting agents for imaging with Positron Emission Tomography (PET) | licensing |
Cancer - Oncology - Autoimmune diseases - Technology - Services | Licensing agreement | |
| 2014-06-03 | Kymab (UK) | chief scientific officer, vice president | nomination | Nomination | ||
| 2014-06-02 | Orion Corporation (Finland) Bayer (Germany) | ODM-201 | prostate cancer | development commercialisation |
Cancer - Oncology | Development agreement |
| 2014-06-02 | Oncobiologics (USA - NJ) Ipca laboratories (India) | biosimilar monoclonal antibody products | development manufacturing production commercialisation |
Cancer - Oncology - Autoimmune diseases | Development agreement | |
| 2014-05-30 | Nicox (France) Eupharmed (Italy) Santen SAS (France) | Cationorm® | dry eye symptoms | distribution |
Ophtalmological diseases | Distribution agreement |
| 2014-05-30 | Qiagen (The Netherlands) Eli Lilly (USA- IN) | assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types | development |
Diagnostic - Cancer - Oncology | Development agreement | |
| 2014-05-30 | Enzo Biochem (USA - NY) Innate Pharma (France) | ProteoStat® products for antibody-drug conjugate (ADC) design | R&D |
Technology - Services | R&D agreement | |
| 2014-05-29 | Uniqure (The Netherlands) Medison Pharma (Israel) | Glybera® (alipogene tiparvovec) | lipoprotein lipase deficiency (LPLD) | distribution |
Rare diseases - Genetic diseases | Distribution agreement |
| 2014-05-28 | Argen-X (The Netherlands-Belgium) Bayer (Germany) | therapeutic antibodies based on arGEN-X\'s SIMPLE Antibody™ technology | collaboration |
Technology - Services | Collaboration agreement |
